NCT02674061View on ClinicalTrials.gov

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

PHASE2CompletedINTERVENTIONAL

Enrollment

376

Participants

Timeline

Start Date

February 25, 2016

Primary Completion Date

September 18, 2019

Study Completion Date

March 18, 2021

Conditions

Ovarian Neoplasms

Interventions

BIOLOGICAL

Pembrolizumab

Administered at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02674061 - Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | Biotech Hunter | Biotech Hunter